Athenex, Inc. (ATNX): Price and Financial Metrics


Athenex, Inc. (ATNX): $3.71

-0.09 (-2.37%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ATNX POWR Grades


  • ATNX scores best on the Value dimension, with a Value rank ahead of 58.75% of US stocks.
  • ATNX's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
  • ATNX's current lowest rank is in the Quality metric (where it is better than 2.94% of US stocks).

ATNX Stock Summary

  • With a year-over-year growth in debt of 148.07%, Athenex Inc's debt growth rate surpasses 93.16% of about US stocks.
  • In terms of volatility of its share price, ATNX is more volatile than 97.05% of stocks we're observing.
  • Athenex Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -59.84%, greater than the shareholder yield of just 4.27% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Athenex Inc are CEMI, TELA, SANW, IMAC, and AVGR.
  • ATNX's SEC filings can be seen here. And to visit Athenex Inc's official web site, go to www.athenex.com.

ATNX Valuation Summary

  • ATNX's EV/EBIT ratio is -3.3; this is 112.36% lower than that of the median Healthcare stock.
  • Over the past 50 months, ATNX's price/earnings ratio has gone up 5.6.
  • ATNX's price/sales ratio has moved down 31.3 over the prior 50 months.

Below are key valuation metrics over time for ATNX.

Stock Date P/S P/B P/E EV/EBIT
ATNX 2020-12-30 6.9 4.8 -9.2 -10.0
ATNX 2020-03-19 5.6 3.0 -4.6 -4.4
ATNX 2019-10-29 9.7 4.8 -6.0 -5.9
ATNX 2018-11-20 9.4 4.8 -6.6 -6.5
ATNX 2018-10-15 11.2 7.1 -9.2 -9.0
ATNX 2017-07-19 49.8 -227.8 -11.7 -12.1

ATNX Price Target

For more insight on analysts targets of ATNX, see our ATNX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.50 Average Broker Recommendation 1.7 (Moderate Buy)

ATNX Stock Price Chart Interactive Chart >

Price chart for ATNX

ATNX Price/Volume Stats

Current price $3.71 52-week high $15.24
Prev. close $3.80 52-week low $3.52
Day low $3.66 Volume 928,200
Day high $3.87 Avg. volume 3,753,178
50-day MA $4.43 Dividend yield N/A
200-day MA $8.02 Market Cap 405.53M

Athenex, Inc. (ATNX) Company Bio


Athenex Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The company was founded in 2003 and is based in Buffalo, New York.


ATNX Latest News Stream


Event/Time News Detail
Loading, please wait...

ATNX Latest Social Stream


Loading social stream, please wait...

View Full ATNX Social Stream

Latest ATNX News From Around the Web

Below are the latest news stories about Athenex Inc that investors may wish to consider to help them evaluate ATNX as an investment opportunity.

Athenex Inks Commercialization Pacts For Tirbanibulin In Australia, New Zealand

Athenex Inc (NASDAQ: ATNX) has entered into licensing agreements and partnerships with Seqirus Pty Ltd, a subsidiary of CSL Limited, and AVIR Pharma Inc to commercialize tirbanibulin. Under the terms of the agreements, Seqirus will have an exclusive license to commercialize tirbanibulin in Australia and New Zealand. AVIR will have an exclusive license to commercialize tirbanibulin in Canada. In addition to upfront payments and milestone payments, the royalty/transfer prices generally range from

Yahoo | July 26, 2021

Athenex Announces Additional Licensing Agreements for Tirbanibulin

Athenex expands its international commercial partnerships for tirbanibulin in Australia, New Zealand and CanadaBUFFALO, N.Y., July 26, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that the Company has entered into licensing agreements and strategic partnerships with Seqirus Pty Ltd (“Seqirus”), a subsid

Yahoo | July 26, 2021

Athenex to Provide Corporate and Financial Update for the Second Quarter 2021 on August 5, 2021

BUFFALO, N.Y., July 22, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the second quarter 2021, on Thursday, August 5, 2021, before the market opens. Athenexs management team will host a conference call and live audio webcast at 8:00am Eastern Time.

Intrado Digital Media | July 22, 2021

Doxorubicin Injection Market 2021 Healthcare, Clinical Reviews, Survey Reports- Hikma, Athenex, Fresenius Kabi, Mylan, Sagent

The Doxorubicin Injection Market report is an in-depth study of the market, along with an analysis of its key segments. The relationship is built through extensive primary and secondary research. In-depth market data is generated through interviews and data collection from

OpenPR | July 20, 2021

Sodium Bicarbonate Injection Market 2021 Insights and In-Depth Analysis- Amphastar, Pfizer, Athenex, Exela, Fresenius Kabi, B Braun, Phebra, Livealth Biopharma, Hunan Jinjian Yaoye, Kelun Pharma

The Sodium Bicarbonate Injection Market report is an in-depth study of the market, along with an analysis of its key segments. The relationship is built through extensive primary and secondary research. In-depth market data is generated through interviews and data collection

OpenPR | July 20, 2021

Read More 'ATNX' Stories Here

ATNX Price Returns

1-mo N/A
3-mo -13.32%
6-mo -73.50%
1-year -66.99%
3-year -79.85%
5-year N/A
YTD -66.46%
2020 -27.57%
2019 20.33%
2018 -20.19%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7656 seconds.